WA
ABBV icon

Wambolt & Associates’s AbbVie ABBV Stock Holding History

Wambolt & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$3.95M Sell
20,771
-1,569
-7% -$292K 1.33% 20
2025
Q1 		$4.61M Sell
22,340
-1,582
-7% -$308K 1.56% 15
2024
Q4 		$4.25M Sell
23,922
-5,138
-18% -$945K 1.36% 19
2024
Q3 		$5.72M Buy
29,060
+565
+2% +$105K 1.56% 12
2024
Q2 		$4.85M Buy
28,495
+948
+3% +$157K 1.41% 13
2024
Q1 		$4.98M Buy
27,547
+97
+0.4% +$16.7K 1.49% 12
2023
Q4 		$4.25M Buy
27,450
+397
+1% +$57.9K 1.39% 9
2023
Q3 		$4.01M Buy
27,053
+640
+2% +$94K 1.46% 5
2023
Q2 		$3.56M Sell
26,413
-50
-0.2% -$7.33K 1.27% 6
2023
Q1 		$4.25M Buy
26,463
+579
+2% +$88.5K 1.51% 6
2022
Q4 		$4.18M Buy
25,884
+386
+2% +$59.2K 1.61% 6
2022
Q3 		$3.42M Buy
25,498
+97
+0.4% +$13.9K 1.45% 7
2022
Q2 		$3.89M Buy
25,401
+742
+3% +$113K 1.56% 7
2022
Q1 		$4.01M Buy
24,659
+1,522
+7% +$221K 1.46% 7
2021
Q4 		$3.13M Buy
23,137
+1,074
+5% +$127K 1.13% 13
2021
Q3 		$2.41M Buy
22,063
+2,055
+10% +$235K 0.97% 18
2021
Q2 		$2.29M Buy
20,008
+2,346
+13% +$264K 0.97% 19
2021
Q1 		$1.92M Buy
17,662
+2,697
+18% +$288K 1% 19
2020
Q4 		$1.6M Buy
14,965
+2,194
+17% +$211K 0.96% 21
2020
Q3 		$1.12M Buy
12,771
+2,669
+26% +$251K 0.84% 30
2020
Q2 		$992K Buy
10,102
+1,860
+23% +$164K 0.78% 36
2020
Q1 		$628K Buy
8,242
+2,566
+45% +$219K 0.65% 51
2019
Q4 		$503K Sell
5,676
-2
-0% -$166 0.38% 85
2019
Q3 		$430K Sell
5,678
-225
-4% -$15.4K 0.36% 97
2019
Q2 		$429K Buy
5,903
+917
+18% +$72.1K 0.36% 91
2019
Q1 		$412K Sell
4,986
-143
-3% -$11.7K 0.37% 87
2018
Q4 		$473K Buy
+5,129
New +$451K 0.52% 61

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Wambolt & Associates's ABBV Position: Q2 2025 in Review

Wambolt & Associates reduced its AbbVie (ABBV) stake by 7% in Q2 2025, selling an estimated $292K and leaving 20,771 shares worth $3.95M. The position accounts for 1.33% of the portfolio, ranked #20.

Wambolt & Associates first reported a position in ABBV in Q4 2018 and has held it in 27 quarters since. The position peaked at $5.72M in Q3 2024. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Wambolt & Associates held 20,771 shares of AbbVie worth $3.95M as of Q2 2025.
  • Wambolt & Associates sold 1,569 AbbVie shares in Q2 2025, an estimated $292K.
  • AbbVie made up 1.33% of Wambolt & Associates's portfolio in Q2 2025, its #20 holding.
  • Wambolt & Associates first reported a position in AbbVie in Q4 2018 and has held it in 27 quarters since.
  • Wambolt & Associates's AbbVie position peaked at $5.72M in Q3 2024.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Wambolt & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.